Karyotypic abnormalities in myelofibrosis following polycythemia vera

被引:42
作者
Andrieux, J
Demory, JL
Caulier, MT
Agape, P
Wetterwald, M
Bauters, F
Lai, JL
机构
[1] Ctr Hosp Reg & Univ Lille, Hop Jeanne De Flandre, Med Genet Lab, F-59037 Lille, France
[2] INSERM U524, Inst Rech Canc Lille, F-59045 Lille, France
[3] CH St Vincent, Hematol Lab, Lille, France
[4] CHRU Lille, Serv Malad Sang, Lille, France
[5] CH Boulogne Sur Mer, Serv Hematol Clin, Boulogne, France
[6] CH Dunkerque, Hematol Serv, Dunkerque, France
关键词
D O I
10.1016/S0165-4608(02)00678-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polycythemia vera (PV) is a chronic myeloproliferative disease characterized by an increase of total red cell volume; in 10% to 15% of cases, bone marrow fibrosis complicates the course of the disease after several years, resulting in a hematologic picture mimicking myelofibrosis with myelocytic metaplasia (MMM). This condition is known as post polycythemic myelofibrosis (PPMF). Among 30 patients with PPMF followed in Northern France, 27 (90%) expressed one or two abnormal clones in myelocytic cell cultures. Of these, 19 (70%) had partial or complete trisomy 1q. This common anomaly either resulted from unbalanced translocations with acrocentric chromosomes, that is, 1 3 14, and 15, or other chromosomes, that is. 1. 6. 7. 9, 16, 19, and Y, or from partial or total duplication of long arm of chromosome 1. A single patient had an isochromosome 1q leading to tetrasomy 1q. In all cases, a common trisomic region spanning 1q21 to 1q32 has been identified. Given that most patients had previously received chemotherapy or radio-phosphorus to control the polycythemic phase of their disease, this Study illustrates the increased frequency of cytogenetic abnormalities after Such treatments: 90% versus 50% in de novo MMM. Moreover, karyotype can be used to distinguish PPMF-where trisomy 1q is the main anomaly- from primary MMM where trisomy 1q is rare and deletions 13q or 20q are far more common. Whether trisomy 1q is or is not a secondary event remains a matter of debate, as well as the role of cytotoxic treatments. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 19 条
[1]   CLINICAL-SIGNIFICANCE OF THE DEL(20Q) CHROMOSOME IN HEMATOLOGIC DISORDERS [J].
AATOLA, M ;
ARMSTRONG, E ;
TEERENHOVI, L ;
BORGSTROM, GH .
CANCER GENETICS AND CYTOGENETICS, 1992, 62 (01) :75-80
[2]  
BERK PD, 1986, SEMIN HEMATOL, V23, P132
[3]   Translocation (1;20)(q32;q13.3) in myelofibrosis following polycythemia vera [J].
Davidovitz, Y ;
Lev, D ;
Ballin, A ;
Tsudik, A ;
Meytes, D .
CANCER GENETICS AND CYTOGENETICS, 1998, 101 (02) :156-158
[4]  
DEMORY JL, 1988, BLOOD, V72, P855
[5]   CHROMOSOME-STUDIES IN 104 PATIENTS WITH POLYCYTHEMIA-VERA [J].
DIEZMARTIN, JL ;
GRAHAM, DL ;
PETITT, RM ;
DEWALD, GW .
MAYO CLINIC PROCEEDINGS, 1991, 66 (03) :287-299
[6]  
Dupriez B, 1996, BLOOD, V88, P1013
[7]  
ELLIS JT, 1986, SEMIN HEMATOL, V23, P144
[8]   Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases [J].
Merlat, A ;
Lai, JL ;
Sterkers, Y ;
Demory, JL ;
Bauters, F ;
Preudhomme, C ;
Fenaux, P .
LEUKEMIA, 1999, 13 (02) :250-257
[9]   Dicentric (1;15) in myeloid disorders [J].
Michaux, L ;
Dierlamm, J ;
Mecucci, C ;
Meeus, P ;
Ameye, G ;
Libouton, JM ;
Verhoef, G ;
Ferrant, A ;
Louwagie, A ;
VerellenDumoulin, C ;
VandenBerghe, H .
CANCER GENETICS AND CYTOGENETICS, 1996, 88 (01) :86-89
[10]  
MILLER JB, 1985, CANCER, V55, P582, DOI 10.1002/1097-0142(19850201)55:3<582::AID-CNCR2820550318>3.0.CO